Summary
OWC Pharmaceutical Research Corp., through its subsidiary, One World Cannabis Ltd., engages in the research and development of cannabis-based medical products. It develops cannabis-based medical products for the treatment of various conditions, including multiple myeloma, psoriasis, post-traumatic stress disorder, chronic pain, and fibromyalgia. The company is also involved in developing cannabis soluble tablet delivery system. In addition, it provides consulting services to companies and governmental agencies related to international medical cannabis protocols and regulations. The company was formerly known as Dynamic Applications Corp. and changed its name to OWC Pharmaceutical Research Corp. in December 2014. OWC Pharmaceutical Research Corp. was founded in 2008 and is based in Ramat Gan, Israel.
History
OWC Pharmaceutical Research Corp. was established in 2012, and is based in Israel. The company’s mission is to develop cannabinoid-based therapies for specific medical conditions, and offer these products to medical markets worldwide.
Mission
Our mission is to develop and produce innovative herbal and pharmaceutical cannabinoid-based therapeutics, meeting and exceeding patient needs, providing effective and safe healthcare outcomes and improving the quality of life for our customers around the world.
Vision
Our vision is to become a leading global provider of cannabinoid-based medicine, with a mission to create opportunities through science, innovation and excellence.
Key Team
Mr. Shmuel De-Saban (CFO & Sec.)
Dr. Oron Yacoby-Zeevi DVM, Ph.D. (Chief Scientific Officer)
Prof. Yuval Ramot (Consultant)
Recognition and Awards
OWC Pharmaceutical has been awarded several awards throughout its history, including the fast-track designation by the U.S. Food and Drug Administration in 2019, as well as several international patents and approvals.
References
